Neurology · Clermont, FL
Neurology studies in Clermont, FL
6 recruiting studies have a site in Clermont.
6 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteers
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment…
GAP Innovations, PBC
- Location
- Clermont, FL + 18 other US sites
- Eligibility basics
- Ages 60–90
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Clermont, FL + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Clermont, FL + 56 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Clermont, FL + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 1/Phase 2
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
AbbVie
- Location
- Clermont, FL + 10 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Clermont, FL + 7 other US sites
- Eligibility basics
- Ages 55–90
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.